Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements reflect label-supported concepts (e.g., increased CV thrombotic and GI bleeding risks; lowest effective dose/shortest duration; GI risk factors include prior ulcer/GI bleeding, older age, alcohol, and anticoagulants). However, many assertions go beyond the label’s wording or scope (e.g., specific platelet/clotting mechanism claims, duration/reversibility claims, and multiple drug-specific hospitalization/rate claims) and several recommended/monitoring statements are not supported by the provided label excerpts.
Category Scores
Accurate Statements
The effect of ibuprofen on platelets/clotting lasts only while the drug is in the body.
Unsupported in provided excerpts (no on-label statement about duration or reversibility of platelet effects).
Taking ibuprofen with blood thinners increases the chance of stomach bleeds.
Supported in concept: risk of serious GI adverse events (bleeding/ulceration/perforation) and increased risk with concomitant anticoagulant use is stated in provided label excerpts (5.2 risk factors mention anticoagulants; 5.12 hematologic toxicity context).
Taking ibuprofen with blood thinners increases the chance of intestinal bleeds.
Supported in concept: GI bleeding/perforation risk includes stomach and intestines (boxed warning/5.2 include “stomach or intestines,” and bleeding/perforation of small/large intestine).
Taking ibuprofen with blood thinners increases the chance of brain bleeds.
Not supported by provided excerpts.
Warfarin is associated with higher rates of hospitalization for bleeding events when combined with ibuprofen.
Not supported by provided excerpts (no hospitalization-rate claim in supplied label text).
Rivaroxaban is associated with higher rates of hospitalization for bleeding events when combined with ibuprofen.
Not supported by provided excerpts.
Apixaban is associated with higher rates of hospitalization for bleeding events when combined with ibuprofen.
Not supported by provided excerpts.
INR levels are monitored if the combination cannot be avoided.
Not supported by provided excerpts (no INR monitoring instruction included).
Kidney function is monitored if the combination cannot be avoided.
Not supported by provided excerpts (no kidney monitoring instruction included).
The interaction matters most during long-term use of ibuprofen rather than occasional single doses.
Not supported by provided excerpts (no relative risk timeframe comparison provided).
Long-term ibuprofen users face higher risks if they already have kidney disease.
Not supported by provided excerpts.
Long-term ibuprofen users face higher risks if they are older.
Supported in concept for GI risk: elderly patients at greater risk for serious GI events (boxed warning).
Long-term ibuprofen users face higher risks if they use alcohol regularly.
Supported in concept: alcohol is listed as a risk factor for GI bleeding/ulceration/perforation in 5.2 risk factors.
Doctors recommend using the lowest dose for the shortest time if ibuprofen cannot be avoided in patients on blood thinners.
Supported: dosing strategy “use the lowest effective dosage for the shortest duration possible” is stated in 2.1 and 5.1/5.2 strategies.
Doctors limit ibuprofen use especially in older adults.
Supported in concept via label risk factor statements: elderly patients at greater risk for serious GI events; longer duration and other factors increase risk. However, the excerpt does not explicitly state “limit use” in older adults as a directive beyond increased risk.
Doctors limit ibuprofen use especially in anyone with prior stomach ulcers.
Supported in concept: prior history of peptic ulcer disease and/or GI bleeding increases risk (5.2 risk factors).
Unsupported Statements
Ibuprofen blocks enzymes that help platelets form clots.
Not supported by provided label excerpts.
Ibuprofen slows the natural process of stopping bleeds.
Not supported by provided label excerpts.
The effect of ibuprofen on platelets/clotting lasts only while the drug is in the body.
Not supported by provided label excerpts.
The effect of ibuprofen usually reverses itself once metabolism finishes.
Not supported by provided label excerpts.
Taking ibuprofen with blood thinners increases the chance of brain bleeds.
Not supported by provided label excerpts.
Ibuprofen and blood thinners weaken different parts of the clotting system.
Not supported by provided label excerpts.
Warfarin is associated with higher rates of hospitalization for bleeding events when combined with ibuprofen.
Provided label excerpts state synergistic effect and increased risk of serious bleeding but do not include hospitalization-rate data.
Rivaroxaban is associated with higher rates of hospitalization for bleeding events when combined with ibuprofen.
Provided label excerpts do not mention rivaroxaban.
Apixaban is associated with higher rates of hospitalization for bleeding events when combined with ibuprofen.
Provided label excerpts do not mention apixaban.
Acetaminophen does not affect platelets.
Not supported by provided CALDOLOR label excerpts.
Acetaminophen remains the preferred choice for most people on blood thinners.
Not supported by provided label excerpts.
Topical NSAIDs such as diclofenac gel reach the local area only.
Not supported by provided label excerpts.
Topical diclofenac gel limits whole-body exposure to bleeding risk.
Not supported by provided label excerpts.
Doctors usually recommend avoiding ibuprofen entirely in patients on blood thinners.
Not supported as a general directive in provided label excerpts (label provides risk minimization strategies and increased risk, but not a blanket recommendation to avoid in all patients on blood thinners).
INR levels are monitored if the combination cannot be avoided.
Not supported by provided label excerpts.
Kidney function is monitored if the combination cannot be avoided.
Not supported by provided label excerpts.
The interaction matters most during long-term use of ibuprofen rather than occasional single doses.
Not supported by provided label excerpts.
Long-term ibuprofen users face higher risks if they already have kidney disease.
Not supported by provided label excerpts.
Contradictions
Low
AI Statement
Doctors usually recommend avoiding ibuprofen entirely in patients on blood thinners.
Label Reference
5.12 / 5.2 strategies and 2.1 emphasize lowest effective dose/shortest duration and monitoring; provided excerpts do not support a blanket “avoid entirely” directive.
Important Omissions
No mention of CABG surgery contraindication (explicitly in CONTRAINDICATIONS and boxed warning context) when making broad statements about “blood thinners” and bleeding risk.
Importance:
Moderate
Boxed warning includes cardiovascular thrombotic risk occurring early and potentially increasing with duration; the provided statements do not capture this labeling nuance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple statements are unsupported (e.g., platelet mechanism, brain bleed, specific hospitalization-rate claims for warfarin/rivaroxaban/apixaban, and monitoring/INR/kidney recommendations). Unsupported specificity could mislead risk framing beyond what the provided label excerpts support. Some risk-minimization concepts are label-consistent (lowest effective dose/shortest duration; higher GI risk with anticoagulants and risk factors such as older age, prior ulcer/GI bleeding, and alcohol).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Numerous claims are not supported by the provided CALDOLOR prescribing information excerpts (especially mechanism/duration/reversibility, CNS/brain bleed, specific hospitalization-rate statements by anticoagulant, and monitoring directives such as INR and kidney function).
Suggested Improvement
Limit assertions to labeling-supported content: (1) boxed warning risks (CV MI/stroke; GI bleeding/ulceration/perforation), (2) label strategies (lowest effective dose/shortest duration), and (3) label-listed GI risk factors (prior ulcer/GI bleeding, longer duration, concomitant anticoagulants/oral corticosteroids/aspirin/SSRIs/SNRIs, smoking, alcohol, older age, poor general health). Remove or rephrase unsupported platelet-mechanism, duration/reversibility, brain bleed, and anticoagulant-specific hospitalization-rate claims; only include monitoring instructions that are explicitly present in the provided label text.